Cargando…

Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors

The ability to non-invasively monitor tumor-infiltrating T cells in vivo could provide a powerful tool to visualize and quantify tumor immune infiltrates. For non-invasive evaluations in vivo, an anti-CD3 mAb was modified with desferrioxamine (DFO) and radiolabeled with zirconium-89 (Zr-89 or (89)Zr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beckford Vera, Denis R., Smith, Christof C., Bixby, Lisa M., Glatt, Dylan M., Dunn, Stuart S., Saito, Ryoichi, Kim, William Y., Serody, Jonathan S., Vincent, Benjamin G., Parrott, Matthew C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841805/ https://www.ncbi.nlm.nih.gov/pubmed/29513764 http://dx.doi.org/10.1371/journal.pone.0193832

Ejemplares similares

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
por: Perk, Lars R., et al.
Publicado: (2009)

Engineering Intrinsically Zirconium‐89 Radiolabeled Self‐Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies
por: Goel, Shreya, et al.
Publicado: (2016)

In Vitro and In Vivo Characterization of (89)Zirconium-Labeled Lintuzumab Molecule
por: Allen, Kevin J. H., et al.
Publicado: (2022)

A new technique for the radiolabelling of mixed leukocytes with zirconium‐89 for inflammation imaging with positron emission tomography
por: Fairclough, M., et al.
Publicado: (2016)

Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89
por: Zhai, Chuangyan, et al.
Publicado: (2019)

Automated light-induced synthesis of (89)Zr-radiolabeled antibodies for immuno-positron emission tomography
por: Klingler, Simon, et al.
Publicado: (2022)

(89)Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
por: Chang, Albert J., et al.
Publicado: (2012)

On the Versatility of Nanozeolite Linde Type L for Biomedical Applications: Zirconium-89 Radiolabeling and In Vivo Positron Emission Tomography Study
por: Lacerda, Sara, et al.
Publicado: (2022)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018)

The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021)

Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability
por: Kang, Chi Soo, et al.
Publicado: (2022)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89
por: Bhatt, Nikunj B., et al.
Publicado: (2017)

Microfluidic Preparation of (89)Zr-Radiolabelled Proteins by Flow Photochemistry
por: Earley, Daniel F., et al.
Publicado: (2021)

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016)

Characterization of Chimeric Antigen Receptor Modified T Cells Expressing scFv-IL-13Rα2 after Radiolabeling with 89Zirconium Oxine for PET Imaging
por: Leland, Pamela, et al.
Publicado: (2023)

Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with (89)Zirconium oxine for PET imaging
por: Leland, Pamela, et al.
Publicado: (2023)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
por: Escorcia, Freddy E., et al.
Publicado: (2018)

Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment
por: Doty, Daniel T., et al.
Publicado: (2020)

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
por: Jagoda, Elaine M., et al.
Publicado: (2019)

Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with (89)Zirconium oxine for PET imaging
por: Leland, Pamela, et al.
Publicado: (2023)

Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis
por: Park, Bok-Nam, et al.
Publicado: (2019)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
por: Laban, Kamil G., et al.
Publicado: (2019)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
por: Mostafa, Ahmed M. A., et al.
Publicado: (2023)

Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development
por: Pandya, Darpan N., et al.
Publicado: (2017)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by (89)Zr-immuno-PET in xenograft bearing mice
por: Chomet, Marion, et al.
Publicado: (2020)

Tumor Colonization and Therapy by Escherichia coli Nissle 1917 Strain in Syngeneic Tumor-Bearing Mice Is Strongly Affected by the Gut Microbiome
por: Gentschev, Ivaylo, et al.
Publicado: (2022)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

Radiolabeled F(ab′)(2)-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models
por: Bellaye, P.-S., et al.
Publicado: (2018)

The effect of resveratrol, curcumin and quercetin combination on immuno-suppression of tumor microenvironment for breast tumor-bearing mice
por: Li, Chenchen, et al.
Publicado: (2023)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®
por: Liapis, Vasilios, et al.
Publicado: (2020)

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
por: Bailly, Clément, et al.
Publicado: (2019)

Radiolabeled Nanoparticles for Multimodality Tumor Imaging
por: Xing, Yan, et al.
Publicado: (2014)

Infiltration of Immune Competent Cells into Primary Tumors and Their Surrounding Connective Tissues in Xenograft and Syngeneic Mouse Models
por: Metzen, Marlon, et al.
Publicado: (2021)

Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model
por: Park, Younghee, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dh529jq0qdvk4onjp64t96h1oh